Brief: Inmune Bio Updates On Alzheimer’S Phase II Clinical Trial And Clinical Hold Issued By FDA

Inmune Bio

18/12/2023 21:56

Dec 18 (Reuters) - INmune Bio Inc  INMB.O :
    * INMUNE BIO PROVIDES UPDATE REGARDING GLOBAL ALZHEIMER’S
PHASE II
CLINICAL TRIAL AND CLINICAL HOLD ISSUED BY THE UNITED STATES FDA
    * INMUNE BIO: ON TRACK TO COMPLETE ENROLLMENT OF PHASE II
CLINICAL
TRIAL IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE & BIOMARKERS OF
INFLAMMATION IN 2024
    * INMUNE BIO INC: RECEIVED NOTIFICATION BY FDA THAT US PHASE
II
TRIAL REMAINS ON FULL CLINICAL HOLD
    * INMUNE BIO INC: FDA CLINICAL HOLD PENDING A REQUEST FOR
ADDITIONAL INFORMATION ON LONG-TERM POTENCY.
    * INMUNE BIO-  TRIAL IS OPEN IN AUSTRALIA, CANADA, UK,
POLAND,
FRANCE, SPAIN AND IS EXPECTED TO OPEN SOON IN SEVERAL ADDITIONAL
EU COUNTRIES

Source text for Eikon:  ID:nGNX4mj52p 
Further company coverage:  INMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))